Role of amino acid hydrophobicity, aromaticity, and molecular volume on IAPP(20–29) amyloid self-assembly
Todd M. Doran
Department of Chemistry, University of Rochester, Rochester, New York 14627
Search for more papers by this authorAlissa J. Kamens
Department of Chemistry, University of Rochester, Rochester, New York 14627
Search for more papers by this authorNadia K. Byrnes
Department of Chemistry, University of Rochester, Rochester, New York 14627
Search for more papers by this authorCorresponding Author
Bradley L. Nilsson
Department of Chemistry, University of Rochester, Rochester, New York 14627
Department of Chemistry, University of Rochester, Rochester, NY 14627===Search for more papers by this authorTodd M. Doran
Department of Chemistry, University of Rochester, Rochester, New York 14627
Search for more papers by this authorAlissa J. Kamens
Department of Chemistry, University of Rochester, Rochester, New York 14627
Search for more papers by this authorNadia K. Byrnes
Department of Chemistry, University of Rochester, Rochester, New York 14627
Search for more papers by this authorCorresponding Author
Bradley L. Nilsson
Department of Chemistry, University of Rochester, Rochester, New York 14627
Department of Chemistry, University of Rochester, Rochester, NY 14627===Search for more papers by this authorAbstract
Aromatic amino acids strongly promote cross-β amyloid formation; whether the amyloidogenicity of aromatic residues is due to high hydrophobicity and β-sheet propensity or formation of stabilizing π–π interactions has been debated. To clarify the role of aromatic residues on amyloid formation, the islet amyloid polypeptide 20–29 fragment [IAPP(20–29)], which contains a single aromatic residue (Phe 23), was adopted as a model. The side chain of residue 23 does not self-associate in cross-β fibrils of IAPP(20–29) (Nielsen et al., Angew Chem Int Ed 2009;48:2118–2121), allowing investigation of the amyloidogenicity of aromatic amino acids in a context where direct π–π interactions do not occur. We prepared variants of IAPP(20–29) in which Tyr, Leu, Phe, pentafluorophenylalanine (F5-Phe), Trp, cyclohexylalanine (Cha), α-naphthylalanine (1-Nap), or β-naphthylalanine (2-Nap) (in order of increasing peptide hydrophobicity) were incorporated at position 23 (SNNXGAILSS-NH2), and the kinetic and thermodynamic effects of these mutations on cross-β self-assembly were assessed. The Tyr, Leu, and Trp 23 variants failed to readily self-assemble at concentrations up to 1.5 mM, while the Cha 23 mutant fibrillized with attenuated kinetics and similar thermodynamic stability relative to the wild-type Phe 23 peptide. Conversely, the F5-Phe, 1-Nap, and 2-Nap 23 variants self-assembled at enhanced rates, forming fibrils with greater thermodynamic stability than the wild-type peptide. These results indicate that the high amyloidogenicity of aromatic amino acids is a function of hydrophobicity, β-sheet propensity, and planar geometry and not the ability to form stabilizing or directing π–π bonds. Proteins 2012;. © 2011 Wiley Periodicals, Inc.
Supporting Information
Additional Supporting Information may be found in the online version of this article.
Filename | Description |
---|---|
PROT_24007_sm_SuppInfo.pdf4.1 MB | Supporting Information |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1 Chiti F, Dobson CM. Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem 2006; 75: 333–366.
- 2
Stefani M.
Toxicity in amyloid diseases. In:
M Ramirez-Alvarado, JW Kelly, CM Dobson, editors.
Protein misfolding diseases, Wiley series on protein and peptide science.
Hoboken:
Wiley;
2010. pp
93–112.
10.1002/9780470572702.ch5 Google Scholar
- 3 Hamley IW. Peptide fibrillization. Angew Chem Int Ed 2007; 46: 8128–8147.
- 4 Greenwald J, Riek R. Biology of amyloid: structure, function and regulation. Structure (Cambridge, MA, USA) 2010; 18: 1244–1260.
- 5 Chiti F, Stefani M, Taddei N, Ramponi G, Dobson CM. Rationalization of the effects of mutations on peptide and protein aggregation rates. Nature 2003; 424: 805–808.
- 6 Makin OS, Atkins E, Sikorski P, Johansson J, Serpell LC. Molecular basis for amyloid fibril formation and stability. Proc Natl Acad Sci USA 2005; 102: 315–320.
- 7 Gazit E. A possible role for π-stacking in the self-assembly of amyloid fibrils. FASEB J 2002; 16: 77–83.
- 8 Tatko CD, Waters ML. Selective aromatic interactions in β-hairpin peptides. J Am Chem Soc 2002; 124: 9372–9373.
- 9 Butterfield SM, Patel PR, Waters ML. Contribution of aromatic interactions to α-helix stability. J Am Chem Soc 2002; 124: 9751–9755.
- 10 Waters ML. Aromatic interactions in model systems. Curr Opin Chem Biol 2002; 6: 736–741.
- 11 Tartaglia GG, Cavalli A, Pellarin R, Caflisch A. The role of aromaticity, exposed surface, and dipole moment in determining protein aggregation rates. Protein Sci 2004; 13: 1939–1941.
- 12 Pawar AP, DuBay KF, Zurdo J, Chiti F, Vendruscolo M, Dobson CM. Prediction of “aggregation-prone” and “aggregation-susceptible” regions in proteins associated with neurodegenerative diseases. J Mol Biol 2005; 350: 379–392.
- 13 Platt GW, Routledge KE, Homans SW, Radford SE. Fibril growth kinetics reveal a region of β2-microglobulin important for nucleation and elongation of aggregation. J Mol Biol 2008; 378: 251–263.
- 14 Porat Y, Mazor Y, Efrat S, Gazit E. Inhibition of islet amyloid polypeptide fibril formation: a potential role for heteroaromatic interactions. Biochemistry 2004; 43: 14454–14462.
- 15 Porat Y, Stepensky A, Ding F-X, Naider D, Gazit E. Completely different amyloidogenic potential of nearly identical peptide fragments. Biopolymers 2003; 69: 161–164.
- 16 Cohen T, Frydman-Marom A, Rechter M, Gazit E. Inhibition of amyloid fibril formation and cytotoxicity by hydroxyindole derivatives. Biochemistry 2006; 45: 4727–4735.
- 17 Porat Y, Abramowitz A, Gazit E. Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism. Chem Biol Drug Des 2006; 67: 27–37.
- 18 Scherzer-Attali R, Pellarin R, Convertino M, Frydman-Marom A, Egoz-Matia N, Peled S, Levy-Sakin M, Shalev DE, Caflisch A, Gazit E, Segal D. Complete phenotypic recovery of an Alzheimer's disease model by a quinone-tryptophan hybrid aggregation inhibitor. PLoS One 2010; 5: e11101.
- 19 Azriel R, Gazit E. Analysis of the minimal amyloid-forming fragment of the islet amyloid polypeptide. J Biol Chem 2001; 276: 34156–34161.
- 20 Marshall KE, Morris KL, Charlton D, O'Reilly N, Lewis L, Walden H, Serpell LC. Hydrophobic, aromatic and electrostatic interactions play a central role in amyloid formation. Biochemistry 2011; 50: 2061–2071.
- 21 Zanuy D, Porat Y, Gazit E, Nussinov R. Peptide sequence and amyloid formation: molecular simulations and experimental study of a human islet amyloid polypeptide fragment and its analogs. Structure (Cambridge, MA, USA) 2004; 12: 439–455.
- 22 Westermark P, Engstrom U, Johnson KH, Westermark GT, Betsholtz C. Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc Natl Acad Sci USA 1990; 87: 5036–5040.
- 23 Tracz SM, Abedini A, Driscoll M, Raleigh DP. Role of aromatic interactions in amyloid formation by peptides derived from human amylin. Biochemistry 2004; 43: 15901–15908.
- 24 Marek P, Abedini A, Song B, Kanungo M, Johnson ME, Gupta R, Zaman W, Wong SS, Raleigh DP. Aromatic interactions are not required for amyloid fibril formation by islet amyloid polypeptide but do influence the rate of fibril formation and fibril morphology. Biochemistry 2007; 46: 3255–3261.
- 25 Chung DM, Dou Y, Baldi P, Nowick JS. The absence of favorable aromatic interactions between β-sheet peptides. J Am Chem Soc 2005; 127: 9998–9999.
- 26 Bemporad F, Taddei N, Stefani M, Chiti F. Assessing the role of aromatic residues in the amyloid aggregation of human muscle acylphosphatase. Protein Sci 2006; 15: 862–870.
- 27 de Groot NS, Aviles FX, Vendrell J, Ventura S. Mutagenesis of the central hydrophobic cluster in Aβ42 Alzheimer's peptide. FEBS J 2006; 273: 658–668.
- 28 Fernandez-Escamilla A-M, Rousseau F, Schymkowitz J, Serrano L. Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins. Nat Biotechnol 2004; 22: 1302–1306.
- 29 Nelson R, Eisenberg D. Recent atomic models of amyloid fibril structure. Curr Opin Struct Biol 2006; 16: 260–265.
- 30 Sawaya MR, Sambashivan S, Nelson R, Ivanova MI, Sievers SA, Apostol MI, Thompson MJ, Balbirnie M, Wiltzius JJW, McFarlane HT, Madsen AO, Riekel C, Eisenberg D. Atomic structures of amyloid cross-β spines reveal varied steric zippers. Nature 2007; 447: 453–457.
- 31 Bowerman CJ, Ryan DM, Nissan DA, Nilsson BL. The effect of increasing hydrophobicity on the self-assembly of amphipathic β-sheet peptides. Mol BioSyst 2009; 5: 1058–1069.
- 32 Senguen FT, Lee NR, Gu X, Ryan DM, Doran TM, Anderson EA, Nilsson BL. Probing aromatic, hydrophobic and steric effects on the self-assembly of an amyloid-β fragment peptide. Mol BioSyst 2011; 7: 486–496.
- 33 Senguen FT, Doran TM, Anderson EA, Nilsson BL. Clarifying the influence of core amino acid hydrophobicity, secondary structure propensity, and molecular volume on amyloid-β 16–22 self-assembly. Mol BioSyst 2011; 7: 497–510.
- 34 Jack E, Newsome M, Stockley PG, Radford SE, Middleton DA. The Organization of aromatic side groups in an amyloid fibril probed by solid-state 2H and 19F NMR spectroscopy. J Am Chem Soc 2006; 128: 8098–8099.
- 35 Madine J, Jack E, Stockley PG, Radford SE, Serpell LC, Middleton DA. Structural insights into the polymorphism of amyloid-like fibrils formed by region 20–29 of amylin revealed by solid-state NMR and X-ray fiber diffraction. J Am Chem Soc 2008; 130: 14990–15001.
- 36 Nielsen JT, Bjerring M, Jeppesen MD, Pedersen RO, Pedersen JM, Hein KL, Vosegaard T, Skrydstrup T, Otzen DE, Nielsen NC. Unique identification of supramolecular structures in amyloid fibrils by solid-state NMR spectroscopy. Angew Chem Int Ed 2009; 48: 2118–2121.
- 37 Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003; 300: 486–489.
- 38 Fauchère J-L, Charton M, Kier LB, Verloop A, Pliska V. Amino acid side chain parameters for correlation studies in biology and pharmacology. Int J Pept Protein Res 1988; 32: 269–278.
- 39 Chiu H-P, Kokona B, Fairman R, Cheng RP. Effect of highly fluorinated amino acids on protein stability at a solvent-exposed position on an internal strand of protein G B1 domain. J Am Chem Soc 2009; 131: 13192–13193.
- 40 Constantini S, Colonna G, Facchiano AM. Amino acid propensities for secondary structures are influenced by the protein structural class. Biochem Biophys Res Commun 2006; 342: 441–451.
- 41 O'Nuallain B, Thakur AK, Williams AD, Bhattacharyya AM, Chen S, Thiagarajan G, Wetzel R. Kinetics and thermodynamics of amyloid assembly using a high-performance liquid chromatography-based sedimentation assay. Methods Enzymol 2006; 413: 34–74.
- 42 Ruschak AM, Miranker AD. Fiber-dependent amyloid formation as catalysis of an existing reaction pathway. Proc Natl Acad Sci USA 2007; 104: 12341–12346.
- 43 Cabaleiro-Lago C, Lynch I, Dawson KA, Linse S. Inhibition of IAPP and IAPP(20–29) fibrillation by polymeric nanoparticles. Langmuir 2010; 26: 3453–3461.
- 44 Nielsen L, Khurana R, Coats A, Frokjaer S, Brange J, Vyas S, Uversky VN, Fink AL. Effect of environmental factors on the kinetics of insulin fibril formation: elucidation of the molecular mechanism. Biochemistry 2001; 40: 6036–6046.
- 45 Abramoff MD, Magelhaes PJ, Ram SJ. Image processing with ImageJ. Biophoton Int 2004; 11: 36–42.
- 46 LeVine H. Quantification of β-sheet amyloid fibril structures with thioflavin T. Methods Enzymol 1999; 309: 274–284.
- 47 Liang Y, Lynn DG, Berland KM. Direct observation of nucleation and growth in amyloid self-assembly. J Am Chem Soc 2010; 132: 6306–6308.
- 48 Marek P, Mukherjee S, Zanni MT, Raleigh DP. Residue-specific, real-time characterization of Lag-phase species and fibril growth during amyloid formation: a combined fluorescence and ir study of p-cyanophenylalanine analogs of islet amyloid polypeptide. J Mol Biol 2010; 400: 878–888.
- 49 Touchette JC, Williams LL, Ajit D, Gallazzi F, Nichols MR. Probing the amyloid-β(1–40) fibril environment with substituted tryptophan residues. Arch Biochem Biophys 2010; 494: 192–197.
- 50 Decatur SM. Elucidation of residue-level structure and dynamics of polypeptides via isotope-edited infrared spectroscopy. Acc Chem Res 2005; 39: 169–175.
- 51 Petty SA, Decatur SM. Experimental evidence for the reorganization of β-strands within aggregates of the Aβ(16–22) peptide. J Am Chem Soc 2005; 127: 13488–13489.
- 52 Mehta AK, Lu K, Childers WS, Liang Y, Dublin SN, Dong J, Snyder JP, Pingali SV, Thiyagarajan P, Lynn DG. Facial symmetry in protein self-assembly. J Am Chem Soc 2008; 130: 9829–9835.
- 53 Liang Y, Pingali SV, Jogalekar AS, Snyder JP, Thiyagarajan P, Lynn DG. Cross-strand pairing and amyloid assembly. Biochemistry 2008; 47: 10018–10026.
- 54 Ashburn TT, Auger M, Peter T. Lansbury J. The structural basis of pancreatic amyloid formation: isotope-edited spectroscopy in the solid state. J Am Chem Soc 1992; 114: 790–791.
- 55 Scrocchi LA, Chen Y, Waschuk S, Wang F, Cheung S, Darabie AA, McLaurin J, Fraser PE. Design of peptide-based inhibitors of human islet amyloid polypeptide fibrillogenesis. J Mol Biol 2002; 318: 697–706.
- 56 Tenidis K, Waldner M, Bernhagen J, Fischle W, Bergmann M, Weber M, Merkle M-L, Voelter W, Brunner H, Kapurniotu A. Identification of a penta- and hexapeptide of islet amyloid polypeptide (IAPP) with amyloidogenic and cytotoxic properties. J Mol Biol 2000; 295: 1055–1071.
- 57 Tatarek-Nossol M, Yan L-M, Schmauder A, Tenidis K, Westermark G, Kapurniotu A. Inhibition of hIAPP amyloid-fibril formation and apoptotic cell death by a designed hIAPP amyloid-core-containing hexapeptide. Chem Biol 2005; 12: 797–809.
- 58 Yan L-M, Tatarek-Nossol M, Velkova A, Kazantzis A, Kapurniotu A. Design of a mimic of nonamyloidogenic and bioactive human islet amyloid polypeptide (IAPP) as nanomolar affinity inhibitor of IAPP cytotoxic fibrillogenesis. Proc Natl Acad Sci USA 2006; 103: 2046–2051.
- 59 Abedini A, Meng F, Raleigh DP. A single-point mutation converts the highly amyloidogenic human islet amyloid polypeptide into a potent fibrillization inhibitor. J Am Chem Soc 2007; 129: 11300–11301.
- 60 Elgersma RC, Mulder GE, Kruijtzer JAW, Posthuma G, Rijkers DTS, Liskamp RMJ. Transformation of the amyloidogenic peptide amylin(20–29) into its corresponding peptoid and retropeptoid: access to both an amyloid inhibitor and template for self-assembled supramolecular tapes. Bioorg Med Chem Lett 2007; 17: 1837–1842.
- 61 Cao P, Meng F, Abedini A, Raleigh DP. The ability of rodent islet amyloid polypeptide to inhibit amyloid formation by human islet amyloid polypeptide has important implications for the mechanism of amyloid formation and the design of inhibitors. Biochemistry 2010; 49: 872–881.
- 62 Armstrong AH, Chen J, McKoy AF, Hecht MH. Mutations that replace aromatic side chains promote aggregation of the alzheimer's aβ peptide. Biochemistry 2011; 50: 4058–4067.
- 63 Goldschmidt L, Teng PK, Riek R, Eisenberg D. Identifying the amylome, proteins capable of forming amyloid-like fibrils. Proc Natl Acad Sci USA 2010; 107: 3487–3492.
- 64 Wu L, McElheny D, Takekiyo T, Keiderling TA. Geometry and efficacy of cross-strand Trp/Trp, Trp/Tyr, and Tyr/Tyr aromatic interaction in a β-hairpin peptide. Biochemistry 2010; 49: 4705–4714.
- 65 Easterhoff D, DiMaio JTM, Doran TM, Dewhurst S, Nilsson BL. Enhancement of HIV-1 infectivity by simple, self-assembling modular peptides. Biophys J 2011; 100: 1325–1334.
- 66 Bowerman CJ, Liyanage W, Federation AJ, Nilsson BL. Tuning β-sheet peptide self-assembly and hydrogelation behavior by modification of sequence hydrophobicity and aromaticity. Biomacromolecules 2011; 12: 2735–2745.
- 67 Reches M, Gazit E. Casting metal nanowires within discrete self-assembled peptide nanotubes. Science 2003; 300: 625–627.
- 68 Takahashi T, Mihara H. Peptide and protein mimetic inhibitors of aβ aggregation. Acc Chem Res 2008; 41: 1309–1318.
- 69 Bartolini M, Andrisano V. Strategies for the inhibition of protein aggregation in human diseases. ChemBioChem 2010; 11: 1018–1035.
- 70 Hirst AR, Escuder B, Miravet JF, Smith DK. High-tech applications of self-assembling supramolecular nanostructured gel-phase materials: from regenerative medicine to electronic devices. Angew Chem Int Ed 2008; 47: 8002–8018.
- 71 Smith AM, Scheibel T. Functional amyloids used by organisms: a lesson in controlling assembly. Macromol Chem Phys 2010; 211: 127–135.
- 72 Otzen D. Functional amyloid. Prion 2010; 4: 256–264.
- 73 Zhao X, Pan F, Xu H, Yaseen M, Shan H, Hauser CAE, Zhang S, Lu JR. Molecular self-assembly and applications of designer peptide amphiphiles. Chem Soc Rev 2010; 39: 3480–3498.
- 74 Cavalli S, Albericio F, Kros A. Amphiphilic peptides and their cross-disciplinary role as building blocks for nanoscience. Chem Soc Rev 2010; 39: 241–263.
- 75 Collier JH, Rudra JS, Gasiorowski JZ, Jung JP. Multi-component extracellular matrices based on peptide self-assembly. Chem Soc Rev 2010; 39: 3413–3424.
- 76 Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ. Naturally secreted oligomers of amyloid-β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002; 416: 535–539.
- 77 Kirkitadze MD, Bitan G, Teplow DB. Paradigm shifts in Alzheimer's disease and other neurodegenerative disorders: the emerging role of oligomeric assemblies. J Neurosci Res 2002; 69: 567–577.